



-12-10-01
BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application) PATENT APPLICATION
Inventor(s): Brudnak, Mark A.)
SC/Serial No.: 09/872,615) Art Unit: 1614
Filed: June 1, 2001)
Title: Genomeceutical and/or)
Enzymatic Composition and)
Method for Treating Autism)

TECH CENTER 1600/2300


DEC 12 2001

RECEIVED

1614
H6 Pre
Q
1-8-02
P.2

CERTIFICATE OF MAILING UNDER 37 C.F.R. Section 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner of Patent and Trademarks, Washington, DC 20231 or to an appropriate alternative address on 12-4-01.


Steven J. Adamson, Reg. No. 32,776

12-4-01
Signature Date

PRELIMINARY AMENDMENT

Commissioner of Patents and Trademarks
Box: Patent Application
Washington, DC 20231

Sir or Madam:

Please enter these amendments prior to examination of the above-identified case.

In the Specification:

Amend the paragraph beginning at page 3, line 20, to read as follows:

Q'
It is believed that these or other conditions cause the digestive tract of a person with autism to function sub-optimally. Two important pioneers of this work, Reichelt and Shattock, observed a significant correlation between the symptoms of autism and an impaired ability to adequately digest peptides/proteins from dairy (casein) and wheat (gluten). During digestion, pre-opioid type compounds in the diet, typically from casein and gluten, are thought to be activated due to an incomplete breakdown of proteins. These exorphins (i.e., casomorphins and gluteomorphins or gliadinomorphin) are then easily transferred